Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, California that focuses on immunotherapy for cancer and immune diseases. Company news frequently highlights progress with its lead ITK inhibitor, soquelitinib, and other clinical-stage candidates in oncology and immunology.
Investors following CRVS news can expect updates on clinical trial milestones, including the registration Phase 3 trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) and randomized trials in atopic dermatitis. Corvus regularly reports interim and final data from Phase 1 and Phase 1b/2 studies, such as results in T cell lymphomas and atopic dermatitis, as well as presentations at major medical meetings like the American Society of Hematology (ASH), the European Society for Medical Oncology (ESMO) and rheumatology congresses.
News releases also cover business updates and financial results, where the company discusses its development strategy for ITK inhibition across cancer and immune diseases, cash runway, and collaborations. Additional announcements may describe progress with ciforadenant in metastatic renal cell cancer, the partner-led mupadolimab program in non-small cell lung cancer, and the Autoimmune Lymphoproliferative Syndrome (ALPS) trial conducted with the National Institute of Allergy and Infectious Diseases.
This CRVS news page aggregates these disclosures so readers can review clinical data announcements, regulatory designations, collaboration updates and corporate events in one place. For those tracking immuno-oncology and immune disease pipelines, Corvus news provides insight into the evolution of its ITK platform and related investigational therapies.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced upcoming presentations of new interim data from their Phase 1 clinical trial of soquelitinib for atopic dermatitis treatment. The data, from Cohorts 1-3 of the randomized, double-blind, placebo-controlled trial, will be presented at the Society for Investigative Dermatology (SID) 2025 Annual Meeting in San Diego.
Dr. Albert S. Chiou from Stanford University Medical Center will present the findings titled 'Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action' through both an oral presentation and poster session on May 8-10, 2025.
The company will discuss these results during their first quarter 2025 business update conference call scheduled for May 8, 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS) has appointed Richard van den Broek to its Board of Directors. Van den Broek, currently managing partner at HSMR Advisors, brings over 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst, and board member.
Van den Broek currently serves on the boards of Pulse Biosciences and Cogstate , and previously served on Pharmacyclics' board until its acquisition by AbbVie in 2015. He holds an A.B. degree from Harvard University and is a Chartered Financial Analyst.
The appointment aims to leverage his expertise in ITK inhibition, which Corvus is developing to modulate and control parallel signaling pathways in the immune system for treating immune diseases and cancers.
Corvus Pharmaceuticals (CRVS) has reported its Q4 and full year 2024 financial results, highlighting progress in its clinical programs. The company's lead drug soquelitinib showed promising interim results in atopic dermatitis trials, with 26% of patients achieving IGA 0/1 and 37% achieving EASI 75 in the first two cohorts, compared to zero in the placebo group.
The company is advancing multiple clinical trials, including a Phase 3 registration trial for peripheral T cell lymphoma (PTCL) and a new Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS). Financial results show cash position of $52.0 million as of December 31, 2024, up from $27.1 million in 2023. R&D expenses increased to $19.4 million for full year 2024, compared to $16.5 million in 2023. The company reported a Q4 net loss of $12.1 million.
Through a registered direct offering and warrant exercises, Corvus raised approximately $48.9 million in 2024. The company expects current cash to fund operations into Q1 2026.
Corvus Pharmaceuticals (NASDAQ: CRVS) has presented additional data from its Phase 1/1b clinical trial of soquelitinib for T cell lymphoma (TCL) treatment at the 16th Annual T-Cell Lymphoma Forum. The trial showed promising results with:
- 39% objective response rate (9 out of 23 evaluable patients)
- 26% complete response rate (6 patients)
- 17.2 months median duration of response
- 6.2 months median progression-free survival
- 30% progression-free survival rate at 18 months
The company is currently conducting a registrational Phase 3 trial enrolling 150 patients with relapsed Peripheral T cell lymphoma, comparing soquelitinib to belinostat or pralatrexate. Soquelitinib has received FDA Orphan Drug Designation for T cell lymphoma and Fast Track designation for relapsed/refractory PTCL treatment.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The clinical-stage biopharmaceutical company's leadership team will engage in one-on-one meetings with investors and participate in a fireside chat presentation scheduled for March 27, 2025, at 12:00 pm ET.
The virtual presentation will be accessible through a webcast that will remain available for 90 days after the event via the company's investor relations website section.
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has scheduled its fourth quarter and full year 2024 financial results announcement for March 25, 2025. The company will host a conference call and webcast at 4:30 pm ET / 1:30 pm PT.
Investors can access the conference call through toll-free domestic (1-800-717-1738) or international (1-646-307-1865) numbers. A webcast will be available through the investor relations section of Corvus' website, with replay access for 90 days following the event.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced the initiation of a Phase 2 clinical trial of soquelitinib for treating Autoimmune Lymphoproliferative Syndrome (ALPS), a rare genetic disease. The trial will be conducted by NIH/NIAID in partnership with Corvus.
The study will enroll up to 30 patients aged 16 or older with confirmed ALPS-FAS, testing two dosing cohorts of 200mg and 400mg twice daily for up to 360 days. The primary endpoint focuses on reducing splenomegaly and lymph node volumes, with secondary endpoints including safety and tolerability.
This marks the third indication for soquelitinib, alongside its ongoing Phase 3 trial for peripheral T cell lymphoma (PTCL) and Phase 1 trial for atopic dermatitis. Corvus plans to initiate an additional Phase 1 trial for solid tumors in Q2 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event. The clinical-stage biopharmaceutical company's leadership team will deliver a corporate overview presentation on Tuesday, February 11, 2025, at 9:20 am ET.
The company will also conduct one-on-one meetings with investors during the conference. A webcast of the presentation will be accessible through the investor relations section of Corvus's website, with availability both live and for 90 days following the event.
Corvus Pharmaceuticals (NASDAQ: CRVS) has released new interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The trial, which includes data from 26 patients across two cohorts, showed promising results with 26% of treated patients achieving IGA 0 or 1 and 37% achieving EASI 75, while no placebo patients reached these endpoints.
The study evaluated two dosing regimens: Cohort 1 with 100 mg twice daily (12 patients) and Cohort 2 with 200 mg once daily (7 patients), against placebo groups. All Cohort 2 patients completed the 28-day treatment period with no significant safety issues or laboratory abnormalities. The trial is designed to enroll 64 patients total across four cohorts, with full results expected in Q2 2025.
FAQ
What is the current stock price of Corvus Pharmaceu (CRVS)?
What is the market cap of Corvus Pharmaceu (CRVS)?
